Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Asthma | 22 | 2021 | 4383 | 2.15 | Why? |
| Food Hypersensitivity | 6 | 2019 | 397 | 1.80 | Why? |
| Rhinovirus | 8 | 2018 | 979 | 1.68 | Why? |
| Rhinitis, Allergic | 7 | 2021 | 704 | 1.17 | Why? |
| Hypersensitivity, Immediate | 2 | 2019 | 134 | 0.94 | Why? |
| Immunoglobulin E | 5 | 2020 | 557 | 0.84 | Why? |
| Omalizumab | 2 | 2019 | 158 | 0.81 | Why? |
| Nasal Provocation Tests | 1 | 2019 | 12 | 0.79 | Why? |
| Enterocolitis | 1 | 2019 | 62 | 0.74 | Why? |
| Allergens | 5 | 2019 | 728 | 0.74 | Why? |
| Dietary Proteins | 1 | 2019 | 112 | 0.74 | Why? |
| Bone Diseases, Developmental | 1 | 2017 | 4 | 0.70 | Why? |
| Food, Formulated | 1 | 2017 | 10 | 0.69 | Why? |
| Anti-Allergic Agents | 1 | 2019 | 167 | 0.65 | Why? |
| Respiratory Hypersensitivity | 2 | 2017 | 103 | 0.63 | Why? |
| Transforming Growth Factor beta | 2 | 2017 | 363 | 0.57 | Why? |
| Bone Density | 1 | 2017 | 335 | 0.52 | Why? |
| Respiratory Sounds | 5 | 2018 | 294 | 0.52 | Why? |
| Receptors, Notch | 1 | 2013 | 59 | 0.51 | Why? |
| Respiratory Syncytial Viruses | 1 | 2017 | 612 | 0.50 | Why? |
| Picornaviridae Infections | 5 | 2018 | 544 | 0.50 | Why? |
| Respiratory Tract Infections | 4 | 2018 | 6817 | 0.45 | Why? |
| Prenatal Exposure Delayed Effects | 2 | 2018 | 319 | 0.42 | Why? |
| TRPA1 Cation Channel | 2 | 2021 | 82 | 0.42 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 290 | 0.41 | Why? |
| Virus Diseases | 2 | 2018 | 3779 | 0.40 | Why? |
| Hypersensitivity | 6 | 2021 | 1137 | 0.40 | Why? |
| Anaphylaxis | 4 | 2021 | 940 | 0.38 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.37 | Why? |
| Diet | 2 | 2020 | 2052 | 0.36 | Why? |
| Skin Tests | 2 | 2018 | 229 | 0.33 | Why? |
| NF-E2-Related Factor 2 | 2 | 2021 | 373 | 0.33 | Why? |
| Tobacco Smoke Pollution | 1 | 2009 | 181 | 0.32 | Why? |
| Interleukin-10 | 1 | 2013 | 1409 | 0.31 | Why? |
| Nasal Polyps | 2 | 2019 | 221 | 0.30 | Why? |
| Child, Preschool | 15 | 2021 | 36283 | 0.27 | Why? |
| Health Services Needs and Demand | 1 | 2018 | 3419 | 0.26 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.26 | Why? |
| Nasal Cavity | 1 | 2008 | 909 | 0.25 | Why? |
| Child | 17 | 2021 | 70012 | 0.25 | Why? |
| Environmental Exposure | 2 | 2013 | 1558 | 0.24 | Why? |
| Greece | 2 | 2019 | 2091 | 0.24 | Why? |
| Neovascularization, Pathologic | 1 | 2006 | 305 | 0.23 | Why? |
| Vascular Endothelial Growth Factor A | 1 | 2006 | 604 | 0.23 | Why? |
| RNA Viruses | 1 | 2008 | 824 | 0.22 | Why? |
| Dermatitis, Atopic | 2 | 2019 | 714 | 0.21 | Why? |
| Biomedical Research | 2 | 2019 | 5270 | 0.20 | Why? |
| TRPV Cation Channels | 1 | 2021 | 88 | 0.20 | Why? |
| Rhinometry, Acoustic | 1 | 2019 | 8 | 0.20 | Why? |
| Sublingual Immunotherapy | 1 | 2020 | 88 | 0.20 | Why? |
| Epinephrine | 2 | 2021 | 323 | 0.20 | Why? |
| Spices | 1 | 2020 | 130 | 0.20 | Why? |
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2019 | 38 | 0.19 | Why? |
| Histamine H1 Antagonists | 1 | 2019 | 79 | 0.19 | Why? |
| DNA, Catalytic | 1 | 2018 | 48 | 0.18 | Why? |
| Respiratory Syncytial Virus Infections | 2 | 2018 | 1234 | 0.18 | Why? |
| International Classification of Diseases | 2 | 2019 | 265 | 0.18 | Why? |
| Staphylococcal Infections | 2 | 2018 | 1099 | 0.18 | Why? |
| Conjunctivitis, Allergic | 1 | 2019 | 94 | 0.18 | Why? |
| Moraxellaceae Infections | 1 | 2017 | 20 | 0.17 | Why? |
| Common Cold | 2 | 2021 | 645 | 0.17 | Why? |
| Th2 Cells | 2 | 2020 | 680 | 0.17 | Why? |
| Respiratory Syncytial Virus Vaccines | 1 | 2018 | 104 | 0.17 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2017 | 92 | 0.16 | Why? |
| Haemophilus Infections | 1 | 2017 | 69 | 0.16 | Why? |
| Infant | 10 | 2019 | 30274 | 0.16 | Why? |
| Desensitization, Immunologic | 2 | 2021 | 574 | 0.15 | Why? |
| Protein Array Analysis | 1 | 2018 | 387 | 0.15 | Why? |
| Interleukin-33 | 1 | 2017 | 120 | 0.15 | Why? |
| Viral Vaccines | 1 | 2017 | 7560 | 0.15 | Why? |
| Bronchodilator Agents | 2 | 2018 | 444 | 0.15 | Why? |
| Humans | 49 | 2021 | 930598 | 0.14 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.14 | Why? |
| Species Specificity | 1 | 2018 | 1356 | 0.14 | Why? |
| Europe | 7 | 2019 | 12702 | 0.13 | Why? |
| Multimorbidity | 1 | 2019 | 703 | 0.13 | Why? |
| Anti-Asthmatic Agents | 1 | 2018 | 427 | 0.13 | Why? |
| Delivery of Health Care | 2 | 2019 | 15909 | 0.12 | Why? |
| Pulmonary Medicine | 1 | 2019 | 706 | 0.12 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.12 | Why? |
| Urticaria | 1 | 2018 | 472 | 0.12 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.12 | Why? |
| Appointments and Schedules | 1 | 2020 | 1204 | 0.12 | Why? |
| Interleukins | 1 | 2017 | 762 | 0.11 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.11 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.11 | Why? |
| Sinusitis | 1 | 2019 | 649 | 0.11 | Why? |
| Epithelial Cells | 2 | 2018 | 3508 | 0.11 | Why? |
| Nasal Mucosa | 1 | 2018 | 1218 | 0.11 | Why? |
| Medication Adherence | 1 | 2020 | 1270 | 0.10 | Why? |
| Allergists | 2 | 2021 | 266 | 0.10 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.09 | Why? |
| Dendritic Cells | 1 | 2017 | 1330 | 0.09 | Why? |
| Global Health | 4 | 2020 | 13911 | 0.09 | Why? |
| Immune Tolerance | 1 | 2013 | 608 | 0.09 | Why? |
| Male | 18 | 2021 | 367725 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Smartphone | 1 | 2019 | 1840 | 0.09 | Why? |
| Pregnancy Trimester, Third | 1 | 2009 | 445 | 0.09 | Why? |
| Chronic Disease | 2 | 2019 | 5139 | 0.08 | Why? |
| Cross Reactions | 1 | 2018 | 4374 | 0.08 | Why? |
| Mass Vaccination | 1 | 2017 | 1101 | 0.08 | Why? |
| Umbilical Veins | 1 | 2006 | 14 | 0.08 | Why? |
| Female | 16 | 2019 | 380317 | 0.08 | Why? |
| Antibodies, Viral | 2 | 2018 | 51949 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Mobile Applications | 2 | 2019 | 3032 | 0.08 | Why? |
| Up-Regulation | 2 | 2021 | 2249 | 0.07 | Why? |
| Seasons | 1 | 2018 | 4071 | 0.07 | Why? |
| Adrenal Cortex Hormones | 2 | 2020 | 6537 | 0.07 | Why? |
| Case-Control Studies | 3 | 2019 | 17671 | 0.07 | Why? |
| Research Design | 2 | 2019 | 5830 | 0.07 | Why? |
| Interferons | 1 | 2017 | 2885 | 0.07 | Why? |
| Immunization | 1 | 2013 | 2019 | 0.07 | Why? |
| Adjuvants, Immunologic | 1 | 2013 | 1709 | 0.06 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.06 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.06 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.06 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.06 | Why? |
| HeLa Cells | 1 | 2006 | 1303 | 0.06 | Why? |
| Brassica | 1 | 2021 | 66 | 0.05 | Why? |
| Influenza Vaccines | 1 | 2017 | 2941 | 0.05 | Why? |
| World Health Organization | 3 | 2019 | 4213 | 0.05 | Why? |
| Antioxidants | 2 | 2021 | 1593 | 0.05 | Why? |
| Risk Factors | 5 | 2019 | 71621 | 0.05 | Why? |
| Fermentation | 1 | 2020 | 156 | 0.05 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.05 | Why? |
| Animals | 4 | 2017 | 78931 | 0.05 | Why? |
| Visual Analog Scale | 1 | 2019 | 151 | 0.05 | Why? |
| Bronchi | 1 | 2006 | 1048 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.05 | Why? |
| Disease Resistance | 1 | 2020 | 236 | 0.05 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.04 | Why? |
| Information Technology | 1 | 2021 | 278 | 0.04 | Why? |
| Vegetables | 1 | 2020 | 340 | 0.04 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.04 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Salmeterol Xinafoate | 1 | 2017 | 28 | 0.04 | Why? |
| Classification | 1 | 2017 | 55 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Fluticasone | 1 | 2017 | 65 | 0.04 | Why? |
| Virus Replication | 1 | 2018 | 14331 | 0.04 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| RNA, Viral | 2 | 2018 | 32276 | 0.04 | Why? |
| Haemophilus influenzae | 1 | 2017 | 196 | 0.04 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.04 | Why? |
| Infant, Newborn | 4 | 2019 | 23105 | 0.04 | Why? |
| Food | 1 | 2019 | 316 | 0.04 | Why? |
| Cytokines | 1 | 2018 | 15010 | 0.04 | Why? |
| Administration, Intranasal | 1 | 2020 | 1132 | 0.04 | Why? |
| Smoking | 1 | 2009 | 3358 | 0.04 | Why? |
| Efficiency | 1 | 2019 | 420 | 0.04 | Why? |
| Injections, Intramuscular | 1 | 2018 | 800 | 0.04 | Why? |
| Endothelial Cells | 1 | 2006 | 2048 | 0.04 | Why? |
| Observer Variation | 1 | 2017 | 622 | 0.04 | Why? |
| Retrospective Studies | 4 | 2019 | 105322 | 0.04 | Why? |
| Reactive Oxygen Species | 1 | 2020 | 1136 | 0.03 | Why? |
| Down-Regulation | 1 | 2021 | 1416 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Eosinophils | 1 | 2020 | 848 | 0.03 | Why? |
| Cell Movement | 1 | 2017 | 695 | 0.03 | Why? |
| Young Adult | 5 | 2019 | 93724 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Nasopharynx | 2 | 2017 | 10224 | 0.03 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.03 | Why? |
| Secondary Prevention | 1 | 2017 | 762 | 0.03 | Why? |
| Pregnancy | 2 | 2018 | 23879 | 0.03 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.03 | Why? |
| Belgium | 1 | 2018 | 2064 | 0.03 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.03 | Why? |
| Surveys and Questionnaires | 3 | 2019 | 43792 | 0.03 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Interferon-beta | 1 | 2017 | 979 | 0.03 | Why? |
| Primary Prevention | 1 | 2017 | 778 | 0.03 | Why? |
| Cell Line | 1 | 2006 | 12040 | 0.03 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.02 | Why? |
| Respiratory Function Tests | 1 | 2017 | 1755 | 0.02 | Why? |
| Oxidative Stress | 1 | 2021 | 2050 | 0.02 | Why? |
| Emergency Treatment | 1 | 2016 | 719 | 0.02 | Why? |
| Disease Models, Animal | 2 | 2017 | 10998 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 13720 | 0.02 | Why? |
| Phenotype | 1 | 2019 | 4037 | 0.02 | Why? |
| Antiviral Agents | 2 | 2018 | 41703 | 0.02 | Why? |
| Aged | 5 | 2021 | 215776 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.02 | Why? |
| Mice | 2 | 2017 | 21357 | 0.02 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Registries | 2 | 2018 | 12327 | 0.02 | Why? |
| Mice, Inbred BALB C | 1 | 2017 | 5814 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Patient Care Team | 1 | 2021 | 3556 | 0.02 | Why? |
| Adult | 5 | 2019 | 244371 | 0.02 | Why? |
| Consensus | 1 | 2021 | 6345 | 0.02 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.02 | Why? |
| Nanoparticles | 1 | 2018 | 2040 | 0.02 | Why? |
| Middle Aged | 5 | 2019 | 270681 | 0.02 | Why? |
| Health Care Surveys | 1 | 2016 | 2942 | 0.02 | Why? |
| Lung Diseases | 1 | 2019 | 2361 | 0.02 | Why? |
| Symptom Assessment | 1 | 2019 | 4967 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2018 | 3129 | 0.02 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Health Surveys | 1 | 2016 | 2841 | 0.02 | Why? |
| Aged, 80 and over | 2 | 2019 | 88759 | 0.02 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Signal Transduction | 1 | 2020 | 7207 | 0.02 | Why? |
| Viruses | 1 | 2017 | 2238 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Primary Health Care | 1 | 2019 | 4839 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.01 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
Papadopoulos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(229)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(363)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_